NO943967D0 - Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider - Google Patents
Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptiderInfo
- Publication number
- NO943967D0 NO943967D0 NO943967A NO943967A NO943967D0 NO 943967 D0 NO943967 D0 NO 943967D0 NO 943967 A NO943967 A NO 943967A NO 943967 A NO943967 A NO 943967A NO 943967 D0 NO943967 D0 NO 943967D0
- Authority
- NO
- Norway
- Prior art keywords
- mammal
- nonself
- suppression
- tolerance
- induction
- Prior art date
Links
- 230000006698 induction Effects 0.000 title 1
- 230000009696 proliferative response Effects 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87128992A | 1992-04-20 | 1992-04-20 | |
| US96177992A | 1992-10-15 | 1992-10-15 | |
| US97773792A | 1992-11-13 | 1992-11-13 | |
| US08/027,127 US5593698A (en) | 1990-10-31 | 1993-03-05 | Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides |
| PCT/US1993/003708 WO1993020842A1 (en) | 1992-04-20 | 1993-04-20 | Suppression of proliferative response and induction of tolerance with polymorphic class ii mhc allopeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO943967L NO943967L (no) | 1994-10-19 |
| NO943967D0 true NO943967D0 (no) | 1994-10-19 |
Family
ID=27487557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943967A NO943967D0 (no) | 1992-04-20 | 1994-10-19 | Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5593698A (no) |
| EP (1) | EP0637249B1 (no) |
| JP (1) | JPH07505892A (no) |
| KR (1) | KR100275656B1 (no) |
| AT (1) | ATE205400T1 (no) |
| AU (1) | AU686101B2 (no) |
| BR (1) | BR9306345A (no) |
| CA (1) | CA2118502A1 (no) |
| DE (1) | DE69330752D1 (no) |
| HU (1) | HUT71310A (no) |
| IL (1) | IL105472A (no) |
| NO (1) | NO943967D0 (no) |
| WO (1) | WO1993020842A1 (no) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| US6156306A (en) * | 1994-08-17 | 2000-12-05 | Albert Einstein College Of Medicine Of Yeshiva University | Pancreatic β-cells for allogeneic transplantation without immunosuppression |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| US7361331B2 (en) * | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| CA2402489C (en) * | 2000-03-15 | 2011-11-01 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| US7348005B2 (en) * | 2000-03-15 | 2008-03-25 | Advanced Research And Technology Institute | Oral tolerance induction by collagen to prevent allograft rejection |
| WO2001089557A2 (en) | 2000-05-24 | 2001-11-29 | The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services | Methods for preventing strokes by inducing tolerance to e-selectin |
| US20030191063A1 (en) | 2000-08-21 | 2003-10-09 | Wraith David Cameron | Peptide selection method |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| AU2003290948A1 (en) * | 2002-11-15 | 2004-06-15 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| AU2008288283B2 (en) | 2007-08-15 | 2013-01-31 | Circassia Limited | Peptides for desensibilization against allergens |
| DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
| CN111879948A (zh) | 2013-10-17 | 2020-11-03 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| WO2015150492A2 (en) * | 2014-04-01 | 2015-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An isolated donor mhc-derived peptide and uses thereof |
| US10906982B2 (en) | 2015-05-15 | 2021-02-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
| US11266730B2 (en) | 2015-09-29 | 2022-03-08 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for BCG therapy |
| KR102745778B1 (ko) | 2016-05-13 | 2024-12-24 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364762A (en) * | 1990-03-21 | 1994-11-15 | Board Of Trustees Of The Leland Stanford Junior University | Major histocompatibility complex (MHC) molecules |
-
1993
- 1993-03-05 US US08/027,127 patent/US5593698A/en not_active Expired - Fee Related
- 1993-04-20 HU HU9403006A patent/HUT71310A/hu unknown
- 1993-04-20 AU AU41083/93A patent/AU686101B2/en not_active Ceased
- 1993-04-20 BR BR9306345A patent/BR9306345A/pt not_active Application Discontinuation
- 1993-04-20 DE DE69330752T patent/DE69330752D1/de not_active Expired - Lifetime
- 1993-04-20 EP EP93910671A patent/EP0637249B1/en not_active Expired - Lifetime
- 1993-04-20 JP JP5518673A patent/JPH07505892A/ja not_active Ceased
- 1993-04-20 CA CA002118502A patent/CA2118502A1/en not_active Abandoned
- 1993-04-20 AT AT93910671T patent/ATE205400T1/de not_active IP Right Cessation
- 1993-04-20 IL IL10547293A patent/IL105472A/en not_active IP Right Cessation
- 1993-04-20 KR KR1019940703715A patent/KR100275656B1/ko not_active IP Right Cessation
- 1993-04-20 WO PCT/US1993/003708 patent/WO1993020842A1/en active IP Right Grant
-
1994
- 1994-10-19 NO NO943967A patent/NO943967D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO943967L (no) | 1994-10-19 |
| EP0637249A4 (en) | 1997-01-08 |
| EP0637249A1 (en) | 1995-02-08 |
| IL105472A (en) | 1999-06-20 |
| CA2118502A1 (en) | 1993-10-28 |
| DE69330752D1 (de) | 2001-10-18 |
| JPH07505892A (ja) | 1995-06-29 |
| AU686101B2 (en) | 1998-02-05 |
| HU9403006D0 (en) | 1994-12-28 |
| ATE205400T1 (de) | 2001-09-15 |
| EP0637249B1 (en) | 2001-09-12 |
| KR950701228A (ko) | 1995-03-23 |
| HUT71310A (en) | 1995-11-28 |
| KR100275656B1 (ko) | 2000-12-15 |
| IL105472A0 (en) | 1993-08-18 |
| US5593698A (en) | 1997-01-14 |
| BR9306345A (pt) | 1998-06-30 |
| AU4108393A (en) | 1993-11-18 |
| WO1993020842A1 (en) | 1993-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO943967D0 (no) | Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider | |
| Raff et al. | Mouse specific bone marrow-derived lymphocyte antigen as a marker for thymus-independent lymphocytes | |
| PT735893E (pt) | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária | |
| Pape et al. | Characterization of Cytolytic Effector Cells in Peripheral Blood of Healthy Individuals and Cancer Patients: II. Cytotoxicity to Allogeneic or Autochthonous Tumor Cells in Tissue Culture | |
| GR3034964T3 (en) | Lymphocyte activity regulation by hla peptides. | |
| WO1998033527A3 (en) | Cancer immunotherapy with semi-allogeneic cells | |
| ES2087163T3 (es) | Preparacion antitumoral que comprende intreleucina-2 e histamina, analogo al de las mismas o agonistas de receptor h2. | |
| CA2093513A1 (en) | Methods and compositions for suppressing allograft rejection in mammals | |
| Golstein et al. | Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions | |
| Wagner | Cell‐mediated immune response in vitro: Independent differentiation of thymocytes into cytotoxic lymphocytes | |
| NZ505834A (en) | Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use | |
| HK1011503A1 (en) | Immunosuppressive compositions | |
| Yang et al. | The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD | |
| Byrne et al. | Adjuvant α-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma | |
| AR002005A1 (es) | Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora, procedimiento para su preparacion, composicion farmaceutica que loscontiene y metodo para la supresion de la respuesta inmune. | |
| Åkerblom et al. | An Immunoaffinity‐Purified Trypanosoma cruzi Antigen Suppresses Cellular Proliferation through a TGF‐β‐Mediated Mechanism | |
| Santoni et al. | Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug treatment in vivo | |
| Billingham et al. | “Adoptive” immunization of animals against skin isografts and its possible implications | |
| Fahey et al. | Immunity to Plasmodium yoelii: kinetics of the generation of T and B lymphocytes that passively transfer protective immunity against virulent challenge | |
| Schmitz et al. | Induction of long‐term graft acceptance by a combination treatment of donor splenocytes and CTLA4Ig in a high responder rat liver transplantation model | |
| Chen et al. | Splenic immune effector and suppressor cells in mice bearing a growing plasmacytoma | |
| Paranjpe et al. | Discussion paper: specific paralysis of the antitumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay | |
| Tsokos et al. | Concanavalin-induced suppressor cells: characterization on the basis of corticosteroid and radiation sensitivity | |
| Röllinghoff et al. | Induction of secondary cytotoxic T-lymphocytes in vitro does not require cell proliferation | |
| Hassan et al. | Corynebacterium parvum stimulation of adherent and non-adherent cytotoxic cells in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |